[HONG KONG,December 31, 2021] Great Bay Bio (GBB), an AI-enabled biotechnology company, announces the participation of FutureX Capital in its Series A roundfundraising.

Great Bay Bio finished A round financing of near USD 10 million in December 1, 2021. The investors include, Proxima Ventures, GL Ventures, Alibaba Entrepreneurs Fund, Alon Capital and FutureX Capital.

“Thanks for the compelling support of FutureX Capital. We are looking forward to working with FutureX to enrich Great Bay Bio’s entrepreneurial ecosystem and accelerate the pace of the application of cutting-edge technologies such as artificial intelligence into drug development platforms,” said Kingsley Leung, Co-founder and Chairman of GBB.

Zhang Hanqin, Partner of FutureX Capital, comments: “FutureX Capital continues to focus on the innovative application of AI technology in the field of scientific research. Based on its in-depth understanding of the pain points of theindustry and rich experience in biologic drug research and development, Great Bay Bio (GBB) has successfully applied AI technology to the whole process of cell line cultureand screening, significantly shortening the R&D time, reducing the cost of R&D trial and error, and boosting the promising biopharmaceutical industry at a high speed, ultimately benefiting every ordinary person. Together with the founding team and our shareholders, we look forward to exploring the possibilities of AI-enabled pharmaceutical R&D and its application in awider range of areas. ”

About FutureX

FutureX Capital is a mid- to late-stage private equity investment platform that focuses on exploring the growth opportunities of the smart era and high-tech industries. It is committed to exploring the investment layout of the smart era and researching the transformation of the investment industry. The main investment areas include artificial intelligence, cloud computing, Internet of Things, chip semiconductors, 5G, computers, ICT+, etc.